Comparison of ROX Index and Surfactant Protein-D with HFNC Outcome in COVID-19 Patients
DOI:
https://doi.org/10.36408/mhjcm.v10i2.924Keywords:
surfactant protein-d, Covid-19, high flow nasal cannula, ROX indexAbstract
Background: In COVID-19, severe clinical deterioration can lead to respiratory distress. High Flow Nasal Cannula (HFNC) is an oxygenation treatment recommended in severe COVID-19 patients, with various studies showing decreased recovery time and intensive care needed. However, instruments to predict HNFC outcomes, specifically in COVID-19, are not yet widely studied. ROX index is a practical instrument proven effective in predicting HFNC outcome in pneumonia while showing high variabilities of optimum time of assessments and cut-off values in COVID-19. Surfactant Protein-D (SP-D) is an alveolar protein showing potential as a biomarker in acute lung injury and respiratory distress. In this study, we analyzed ROX index and SP-D potential as HFNC outcome predictors in COVID-19 patients.
Methods: This prospective study recruited severe and critical COVID-19 patients treated with HFNC. Patient characteristics, laboratory values including initial serum SP-D values, and ROX index were recorded. Significant differences were analyzed using Chi-Square and Mann-Whitney tests. Receiver operating characteristic (ROC) analysis was used to determine HFNC outcome predictive abilities of ROX index and serum SP-D.
Result: 31 subjects with successful HFNC outcomes in 19 subjects and failed HFNC outcomes in 12 subjects were included in this study. ROX index and SP-D value were significantly higher in subjects with successful HFNC compared to failed HFNC (p < 0.05). ROX index at 6, 12, and 24 hours showed good HFNC outcome predictive ability (AUC > 0.7, p < 0.05).
Conclusion: Successful HFNC outcome in COVID-19 was significantly related to higher ROX index and serum SP-D values. ROX index also showed good potential as an HFNC outcome predictor in COVID-19 patients.
Downloads
References
1. Gibson PG, Qin L, Puah SH. COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS. Medical Journal of Australia. 2020;213(2):54–6.
2. Chandel A, Patolia S, Brown AW, Collins AC, Sahjwani D, Khangoora V, et al. High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success. Respir Care. 2021 Jun;66(6):909–19.
3. Ospina-Tascón GA, Calderón-Tapia LE, García AF, Zarama V, Gómez-Álvarez F, Álvarez-Saa T, et al. Effect of High-Flow Oxygen Therapy vs Conventional Oxygen Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients With Severe COVID-19. JAMA. 2021 Dec;326(21):2161.
4. Roca O, Messika J, Caralt B, García-de-Acilu M, Sztrymf B, Ricard JD, et al. Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. Journal of critical care. 2016 Oct;35:200–5.
5. Prakash J, Bhattacharya PK, Yadav AK, Kumar A, Tudu LC, Prasad K. ROX index as a good predictor of high flow nasal cannula failure in COVID-19 patients with acute hypoxemic respiratory failure: A systematic review and meta-analysis. Journal of Critical Care. 2021;66:102–8.
6. Kerget B, Kerget F, Koçak AO, Kızıltunç A, Araz Ö, Uçar EY, et al. Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Lung. 2020;198(5):777–84.
7. Tong M, Xiong Y, Zhu C, Xu H, Zheng Q, Jiang Y, et al. Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity. BMC Infectious Diseases. 2021 Dec;21(1):737.
8. Marin BG, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, et al. Predictors of COVID‐19 severity: A literature review. Reviews in Medical Virology. 2021 Jan;31(1):1–10.
9. Starke KR, Petereit-Haack G, Schubert M, Kämpf D, Schliebner A, Hegewald J, et al. The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis, and Meta-Regression. International Journal of Environmental Research and Public Health. 2020 Aug;17(16):5974.
10. Okada T, Lee BW, Ogami A, Oyabu T, Myojo T. Inhalation of titanium dioxide (P25) nanoparticles to rats and changes in surfactant protein (SP-D) levels in bronchoalveolar lavage fluid and serum. Nanotoxicology. 2019 Nov;13(10):1396–408.
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2023 Achmad Syamsufandi Rozi, Ngakan Putu Parsama Putra , Ungky Agus Setyawan, Aditya Sri Listyoko
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
